Bioventus (BVS) Invested Capital (2020 - 2026)

Bioventus' Invested Capital history runs 7 years deep, the most recent figure standing at $18.8 million for Q1 2026.

• Quarterly Invested Capital rose 77.34% year-over-year to $18.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.0 million (down 52.74% YoY) and the FY2025 annual result came in at $15.0 million, down 45.13% from the prior year.
• Invested Capital was $18.8 million for Q1 2026 at Bioventus, up from $15.0 million in the prior quarter.
• Across five years, Invested Capital topped out at $41.3 million in Q2 2023 and bottomed at $10.6 million in Q1 2025.
• A 5-year average of $24.0 million and a median of $21.4 million in 2022 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2022 — Invested Capital surged 108.68% — and 2025, when it sank 70.83%.
• Bioventus' Invested Capital stood at $33.1 million in 2022, then dropped by 15.76% to $27.8 million in 2023, then fell by 1.83% to $27.3 million in 2024, then sank by 45.13% to $15.0 million in 2025, then increased by 25.0% to $18.8 million in 2026.
• Business Quant data shows BVS's Invested Capital at $18.8 million in Q1 2026, $15.0 million in Q4 2025, and $11.2 million in Q3 2025.